Diclofenac Potassium
Brand names: Lofena, Cambia, Diclofenac Potassium, Zipsor
At a glance
- Medicare prescriptions, 2024
- 236,561
- Medicare drug cost
- $66.9M
- Average cost per prescription
- $283
- Clinicians who prescribed it
- 6,318
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
Carefully consider the potential benefits and risks of LOFENA ™ ( diclofenac potassium tablets, USP) and other treatment options before deciding to use LOFENA. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS: Gastrointestinal Bleeding, Ulceration, and Perforation ). LOFENA is indicated: For treatment of primary dysmenorrhea For relief of mild to moderate pain For relief of the signs and symptoms of osteoarthritis For relief of the signs and symptoms of rheumatoid arthritis
From the FDA-approved prescribing information (label dated January 2024). Full labels on DailyMed (opens in a new tab)
Boxed warning
WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS Cardiovascular Thrombotic Events Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use (see WARNINGS ). LOFENA™ are contraindicated in the setting of coronary artery bypass graft (CABG) surgery (see CONTRAINDICATIONS, WARNINGS ). Gastrointestinal Bleeding, Ulceration, and Perforation NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI…
The FDA’s strongest warning on a label. It doesn’t mean the drug is unsafe for most people; talk to your doctor or pharmacist before stopping or changing any medicine.
Who prescribes it
- General Practice 26.8%
- Internal Medicine 18.0%
- Family Medicine 14.9%
- Nurse Practitioners 9.1%
- Pain Medicine 4.0%
- Rheumatology 3.7%
- Physician Assistants 3.7%
- Neurology 3.1%
- Physical Medicine & Rehabilitation (PM&R) 2.5%
- Orthopedic Surgery 2.4%
- Podiatrists 2.4%
- Sports Medicine 1.7%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 245% from 2019 to 2024.
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 5 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Carwin Pharmaceutical Associates, LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 25 mg | yellow round tablet, 5 mm | A 25 |
Marlex Pharmaceuticals, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 50 mg | white round tablet, 8 mm | M D5 |
Nivagen Pharmaceuticals, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 25 mg | white round tablet, 7 mm | DP 25 |
Nivagen Pharmaceuticals, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 50 mg | white powder | |
Umedica Laboratories USA Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 50 mg | white powder | |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
No FDA-reported recalls since 2020.
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.